Aprépitant pour la prévention des nausées et vomissements induits par une chimiothérapie à base de cisplatine : étude observationnelle

Autor: Latour Jf, Tissier F, Combes Jd, S. Labidi, Galy G, Bertrand Favier, Auger A

Publikováno v: Bulletin du Cancer. 96:141-145

Aprepitant is actually recommended in the prevention of nausea and vomiting induced by high emetic risk chemotherapy using cisplatin. We performed an observational prospective study on 101 patients evaluating the efficacy of aprepitant in the clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7912d2e7d69e99c3eea78df2d68af75
https://doi.org/10.1684/bdc.2008.0819

Antibodies against high-risk human papillomavirus proteins as markers for noncervical HPV-related cancers in a Black South African population, according to HIV status.

Autor: Singini MG; International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.; National Cancer Registry, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg, South Africa., Muchengeti M; National Cancer Registry, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg, South Africa.; School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.; South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa., Sitas F; Center for Primary Health Care and Equity, School of Population Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.; Menzies Center of Health Policy, School of Public Health, University of Sydney, Sydney, New South Wales, Australia., Chen WC; National Cancer Registry, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg, South Africa.; Strengthening Oncology Services Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.; Sydney Brenner Institute for Molecular Bioscience, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Combes JD; International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France., Waterboer T; Infections and Cancer Epidemiology Division, German Cancer Research Center (DKFZ), Heidelberg, Germany., Clifford GM; International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Jul 15; Vol. 155 (2), pp. 251-260. Date of Electronic Publication: 2024 Apr 05.

State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.

Autor: Engels EA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA., Shiels MS; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA., Barnabas RV; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA., Bohlius J; University of Basel, Basel, Switzerland.; Department for Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Allschwil, Switzerland., Brennan P; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France., Castilho J; Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Chanock SJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA., Clarke MA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA., Coghill AE; Department of Cancer Epidemiology and Center for Immunization and Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA., Combes JD; International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France., Dryden-Peterson S; Brigham and Women's Hospital, Boston, Massachusetts, USA.; Harvard School of Public Health, Boston, Massachusetts, USA., D'Souza G; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Gopal S; Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA., Jaquet A; National Institute for Health and Medical Research (INSERM), UMR, 1219, Research Institute for Sustainable Development (IRD), EMR 271, Bordeaux Population, Health Centre, University of Bordeaux, Bordeaux, France., Lurain K; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Makinson A; Infectious Disease Department, CHU La Colombière, Montpellier & Inserm U1175, University of Montpellier, Montpellier, France., Martin J; Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA., Muchengeti M; National Cancer Registry, National Health Laboratory Service, Johannesburg, South Africa.; Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.; South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa., Newton R; MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, Uganda.; University of York, York, UK., Okuku F; Uganda Cancer Institute, Kampala, Uganda., Orem J; Uganda Cancer Institute, Kampala, Uganda., Palefsky JM; Department of Medicine, University of California, San Francisco, California, USA., Ramaswami R; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Robbins HA; Genomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France., Sigel K; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Silver S; George Washington University, Washington, DC, USA., Suneja G; Department of Radiation Oncology, Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, USA., Yarchoan R; HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA., Clifford GM; International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.

Publikováno v: International journal of cancer [Int J Cancer] 2024 Feb 15; Vol. 154 (4), pp. 596-606. Date of Electronic Publication: 2023 Sep 15.

Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.

Autor: Hu-Heimgartner K; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Lang N; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Ayme A; Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Ming C; Department of Clinical Research, Faculty of Medicine, University of Basel, Basel, Switzerland., Combes JD; Infections and Cancer Epidemiology Group, International Agency for Research on Cancer, Lyon, France., Chappuis VN; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Vazquez C; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Friedlaender A; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Vuilleumier A; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Bodmer A; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Viassolo V; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Sandoval JL; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland., Chappuis PO; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland.; Department of Diagnostics, Hôpitaux Universitaires de Genève, Geneva, Switzerland., Labidi-Galy SI; Department of Oncology, Hôpitaux Universitaires de Genève, 4, Rue Gabrielle Perret-Gentil, Geneva, 1205, Switzerland. intidhar.labidi-galy@hcuge.ch.; Center of Translational Research in Onco-Hematology, Faculty of Medicine, University of Geneva, Swiss Cancer Center Leman, Genève, Switzerland. intidhar.labidi-galy@hcuge.ch.

Publikováno v: Familial cancer [Fam Cancer] 2023 Jul; Vol. 22 (3), pp. 283-289. Date of Electronic Publication: 2023 Apr 29.

Estimating the prevalence of Epstein-Barr virus in primary gastric lymphoma: a systematic review and meta-analysis.

Autor: Hirabayashi M; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), 25 avenue Tony Garnier, CS 90627, 69633, Lyon CEDEX 07, France., Traverse-Glehen A; Hospices Civils de Lyon, Institut de Pathologie Multisite, Hôpital Lyon-Sud, Pierre Bénite, France.; Centre International de Recherche en Infectiologie (CIRI) INSERM U1111 - CNRS UMR5308, Université Claude Bernard Lyon I - ENS de Lyon, Lyon, France., Combes JD; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), 25 avenue Tony Garnier, CS 90627, 69633, Lyon CEDEX 07, France., Clifford GM; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), 25 avenue Tony Garnier, CS 90627, 69633, Lyon CEDEX 07, France., de Martel C; Early Detection, Prevention and Infections Branch, International Agency for Research on Cancer (IARC/WHO), 25 avenue Tony Garnier, CS 90627, 69633, Lyon CEDEX 07, France. demartelc@iarc.who.int.

Publikováno v: Infectious agents and cancer [Infect Agent Cancer] 2023 Feb 10; Vol. 18 (1), pp. 8. Date of Electronic Publication: 2023 Feb 10.